London · Delayed Price · Currency is GBP · Price in USD TG Therapeutics Company Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A.
for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.
The company was incorporated in 1993 and is based in Morrisville, North Carolina.
| Country | United States |
| Founded | 1993 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 338 |
| CEO | Michael Weiss |
Contact Details
Address: 3020 Carrington Mill Blvd. Morrisville, Delaware 27560 United States | |
| Phone | 212 554 4484 |
| Website | tgtherapeutics.com |
Stock Details
| Ticker Symbol | 0VGI |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US88322Q1085 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Weiss | Chief Executive Officer |
| Sean Power | Chief Financial Officer |